Novel therapeutic targets in myeloma bone disease

British Journal of Pharmacology

Volumn 171, Issue 16, 2014, Pages 3765-3776

  Webb, S L ^a   Edwards, C M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; ADIPONECTIN; B CELL ACTIVATING FACTOR; BISPHOSPHONIC ACID DERIVATIVE; BRUTON TYROSINE KINASE; DICKKOPF 1 PROTEIN; EPHRIN B2; EPHRIN RECEPTOR B4; GROWTH FACTOR INDEPENDENCE 1 PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEASOME; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SCLEROSTIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; BONE DENSITY CONSERVATION AGENT; IMMUNOLOGIC FACTOR; PROTEINASE INHIBITOR;

BONE ATROPHY; BONE DISEASE; BONE REMODELING; CELL ACTIVITY; CELL MATURATION; CELL STIMULATION; CLINICAL FEATURE; DISEASE COURSE; DRUG CHOICE; DRUG TARGETING; HUMAN; IMMUNE SYSTEM; MYELOMA; MYELOMA BONE DISEASE; NONHUMAN; OSTEOBLAST; OSTEOCLAST ACTIVITY; OSTEOLYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BONE DISEASES; COMPLICATION; IMMUNOLOGY; METABOLISM; MULTIPLE MYELOMA;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; DIPHOSPHONATES; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE MYELOMA; PROTEASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84904968136     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12742     Document Type: Review

References (148)

1. Abe M, Kido S, Hiasa M, Nakano A, Oda A, Amou H, et-al. (2006). BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma. Leukemia 20: 1313-1315.
2. Adams J, (2002). Development of the proteasome inhibitor PS-341. Oncologist 7: 9-16.
3. Adulkadyrov KSGN, Khuazheva NK, Woolf R, Haltom E, Borgstein NG, Knight R, et-al. (2009). ACE-011, a soluble activin receptor type IIa IgG-Fc fusion protein, increases hemoglobin (Hb) and improves bone lesions in multiple myeloma patients receiving myelosuppressive chemotherapy:preliminary analysis. Blood 114: 749-750.
4. Agholme F, Li X, Isaksson H, Ke HZ, Aspenberg P, (2010). Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res 25: 2412-2418.
5. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et-al. and CGTP Collaborators (2013a). The Concise Guide to PHARMACOLOGY 2013/14: Catalytic receptors. Br J Pharmacol 170: 1676-1705.
6. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et-al. and CGTP Collaborators (2013b). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
7. Allan EH, Hausler KD, Wei T, Gooi JH, Quinn JM, Crimeen-Irwin B, et-al. (2008). EphrinB2 regulation by PTH and PTHrP revealed by molecular profiling in differentiating osteoblasts. J Bone Miner Res 23: 1170-1181.
8. Anderson G, Gries M, Kurihara N, Honjo T, Anderson J, Donnenberg V, et-al. (2006). Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 107: 3098-3105.
9. Bafico A, Liu G, Yaniv A, Gazit A, Aaronson SA, (2001). Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat Cell Biol 3: 683-686.
10. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, et-al. (2001). Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10: 537-543.
11. Balemans W, Patel N, Ebeling M, Van Hul E, Wuyts W, Lacza C, et-al. (2002). Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 39: 91-97.
12. Bates AL, Mundy GR, Edwards CM, (2007). Myeloma cells decrease ephb4 expression in osteoblasts: a novel mechanism for regulation of bone formation in multiple myeloma. J Bone Miner Res 22 (S309): (abstract).
13. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et-al. (1996). Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 334: 488-493.
14. Bergsagel PL, Mateos MV, Gutierrez NC, Rajkumar SV, San Miguel JF, (2013). Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood 121: 884-892.
15. Berner HS, Lyngstadaas SP, Spahr A, Monjo M, Thommesen L, Drevon CA, et-al. (2004). Adiponectin and its receptors are expressed in bone-forming cells. Bone 35: 842-849.
16. van Bezooijen RL, ten Dijke P, Papapoulos SE, Lowik CW, (2005). SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 16: 319-327.
17. Boyce BF, Xing L, (2008). Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 473: 139-146.
18. Breitkreutz I, Raab MS, Vallet S, Hideshima T, Raje N, Mitsiades C, et-al. (2008). Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 22: 1925-1932.
19. Brosh N, Sternberg D, Honigwachs-Sha'anani J, Lee BC, Shav-Tal Y, Tzehoval E, et-al. (1995). The plasmacytoma growth inhibitor restrictin-P is an antagonist of interleukin 6 and interleukin 11. Identification as a stroma-derived activin A. J Biol Chem 270: 29594-29600.
20. Brunetti G, Oranger A, Mori G, Specchia G, Rinaldi E, Curci P, et-al. (2011). Sclerostin is overexpressed by plasma cells from multiple myeloma patients. Ann N Y Acad Sci 1237: 19-23.
21. Butler CM, Gold EJ, Risbridger GP, (2005). Should activin betaC be more than a fading snapshot in the activin/TGFbeta family album? Cytokine Growth Factor Rev 16: 377-385.
22. Chang X, Zhu Y, Shi C, Stewart AK, (2013). Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma. Acta Biochim Biophys Sin (Shanghai) 46: 240-253.
23. Chantry AD, Heath D, Mulivor AW, Pearsall S, Baud'huin M, Coulton L, et-al. (2010). Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. J Bone Miner Res 25: 2633-2646.
24. Chauhan D, Auclair D, Robinson EK, Hideshima T, Li G, Podar K, et-al. (2002). Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene 21: 1346-1358.
25. Chen XX, Baum W, Dwyer D, Stock M, Schwabe K, Ke HZ, et-al. (2013). Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis. Ann Rheum Dis 72: 1732-1736.
26. Choi SJ, Cruz JC, Craig F, Chung H, Devlin RD, Roodman GD, et-al. (2000). Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 96: 671-675.
27. Christoulas D, Terpos E, Dimopoulos MA, (2009). Pathogenesis and management of myeloma bone disease. Expert Rev Hematol 2: 385-398.
28. Clezardin P, (2013). Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities. BoneKEy Rep 2: 267.
29. Coleman R, Gnant M, Morgan G, Clezardin P, (2012). Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst 104: 1059-1067.
30. Colucci S, Brunetti G, Oranger A, Mori G, Sardone F, Specchia G, et-al. (2011). Myeloma cells suppress osteoblasts through sclerostin secretion. Blood Cancer J 1: e27.
31. Croucher PI, Shipman CM, Lippitt JM, Perry M, Asosingh K, Hijzen A, et-al. (2001). Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98: 3534-3540.
32. Darnay BG, Besse A, Poblenz AT, Lamothe B, Jacoby JJ, (2007). TRAFs in RANK signaling. Adv Exp Med Biol 597: 152-159.
33. Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, Vande Broek I, et-al. (2009). Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma. Cancer Res 69: 5307-5311.
34. Deli A, Kreidl E, Santifaller S, Trotter B, Seir K, Berger W, et-al. (2008). Activins and activin antagonists in hepatocellular carcinoma. World J Gastroenterol 14: 1699-1709.
35. DiMascio L, Voermans C, Uqoezwa M, Duncan A, Lu D, Wu J, et-al. (2007). Identification of adiponectin as a novel hemopoietic stem cell growth factor. J Immunol 178: 3511-3520.
36. Dowling CR, Risbridger GP, (2000). The role of inhibins and activins in prostate cancer pathogenesis. Endocr Relat Cancer 7: 243-256.
37. D'Souza S, del Prete D, Jin S, Sun Q, Huston AJ, Kostov FE, et-al. (2011). Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease. Blood 118: 6871-6880.
38. Edwards CM, Edwards JR, Lwin ST, Esparza J, Oyajobi BO, McCluskey B, et-al. (2008). Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 111: 2833-2842.
39. Fizazi KLA, Mariette X, Body JJ, Rahim Y, Gralow JR, Gao G, et-al. (2009). Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 27: 1564-1571.
40. Fowler JA, Lwin ST, Drake MT, Edwards JR, Kyle RA, Mundy GR, et-al. (2011). Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. Blood 118: 5872-5882.
41. Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA, et-al. (2009). Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114: 371-379.
42. Futakuchi M, Nannuru KC, Varney ML, Sadanandam A, Nakao K, Asai K, et-al. (2009). Transforming growth factor-beta signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation. Cancer Sci 100: 71-81.
43. Galson DL, Silbermann R, Roodman GD, (2012). Mechanisms of multiple myeloma bone disease. BoneKEy Rep 1: 135.
44. Garrett IR, Chen D, Gutierrez G, Zhao M, Escobedo A, Rossini G, et-al. (2003). Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 111: 1771-1782.
45. Gilks CB, Bear SE, Grimes HL, Tsichlis PN, (1993). Progression of interleukin-2 (IL-2)-dependent rat T cell lymphoma lines to IL-2-independent growth following activation of a gene (Gfi-1) encoding a novel zinc finger protein. Mol Cell Biol 13: 1759-1768.
46. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S, (2001). Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98: 3527-3533.
47. Gkotzamanidou M, Dimopoulos MA, Kastritis E, Christoulas D, Moulopoulos LA, Terpos E, (2012). Sclerostin: a possible target for the management of cancer-induced bone disease. Expert Opin Ther Targets 16: 761-769.
48. Gobbi G, Sangiorgi L, Lenzi L, Casadei R, Canaider S, Strippoli P, et-al. (2002). Seven BMPs and all their receptors are simultaneously expressed in osteosarcoma cells. Int J Oncol 20: 143-147.
49. Grimes HL, Chan TO, Zweidler-McKay PA, Tong B, Tsichlis PN, (1996). The Gfi-1 proto-oncoprotein contains a novel transcriptional repressor domain, SNAG, and inhibits G1 arrest induced by interleukin-2 withdrawal. Mol Cell Biol 16: 6263-6272.
50. Gunn WG, Conley A, Deininger L, Olson SD, Prockop DJ, Gregory CA, (2006). A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 24: 986-991.
51. Han J-H, Choi SJ, Kurihara N, Koide M, Oba Y, Roodman GD, (2001). Macrophage inflammatory protein-1α is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor κB ligand. Blood 97: 3349-3353.
52. Hashimoto M, Shoda A, Inoue S, Yamada R, Kondo T, Sakurai T, et-al. (1992). Functional regulation of osteoblastic cells by the interaction of activin-A with follistatin. J Biol Chem 267: 4999-5004.
53. Hashimoto T, Abe M, Oshima T, Shibata H, Ozaki S, Inoue D, et-al. (2004). Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma. Br J Haematol 125: 38-41.
54. Heider U, Kaiser M, Muller C, Jakob C, Zavrski I, Schulz CO, et-al. (2006). Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol 77: 233-238.
55. Heider U, Kaiser M, Mieth M, Lamottke B, Rademacher J, Jakob C, et-al. (2009). Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment. Eur J Haematol 82: 31-38.
56. Henry DHCL, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, et-al. (2011). Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29: 1125-1132.
57. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, et-al. (2000). Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96: 2943-2950.
58. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC, (2007). Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7: 585-598.
59. Hirai H, Maru Y, Hagiwara K, Nishida J, Takaku F, (1987). A novel putative tyrosine kinase receptor encoded by the eph gene. Science 238: 1717-1720.
60. Hongming H, Jian H, (2009). Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6. Leuk Res 33: 115-122.
61. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, et-al. (2010). Identification of a primary target of thalidomide teratogenicity. Science 327: 1345-1350.
62. Jin SDS, Sun Q, Sammut B, Grimes HL, Roodman DG, Galson DL, (2011). The transcription repressor Gfi1 directly interacts with the Runx2 gene in osteoblast precursors to mediate repression by multiple myeloma cells via TNFalpha, leading to blocked osteoblast differentiation. J Bone Miner Res 26 (S1): S180.
63. Jurimae J, Rembel K, Jurimae T, Rehand M, (2005). Adiponectin is associated with bone mineral density in perimenopausal women. Horm Metab Res 37: 297-302.
64. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et-al. (1999). OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397: 315-323.
65. Kuehl WM, Bergsagel PL, (2002). Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2: 175-187.
66. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et-al. (2003). Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78: 21-33.
67. Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S, et-al. (2007). American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25: 2464-2472.
68. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et-al. (1998). Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176.
69. Lawasut P, Chauhan D, Laubach J, Hayes C, Fabre C, Maglio M, et-al. (2012). New proteasome inhibitors in myeloma. Curr Hematol Malig Rep 7: 258-266.
70. Lecouvet FE, Vande Berg BC, Maldague BE, Michaux L, Laterre E, Michaux JL, et-al. (1997). Vertebral compression fractures in multiple myeloma. Part I. Distribution and appearance at MR imaging. Radiology 204: 195-199.
71. Lee JW, Chung HY, Ehrlich LA, Jelinek DF, Callander NS, Roodman GD, et-al. (2004). IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 103: 2308-2315.
72. Lee SH, Kim T, Jeong D, Kim N, Choi Y, (2008). The tec family tyrosine kinase Btk Regulates RANKL-induced osteoclast maturation. J Biol Chem 283: 11526-11534.
73. Lenchik L, Register TC, Hsu FC, Lohman K, Nicklas BJ, Freedman BI, et-al. (2003). Adiponectin as a novel determinant of bone mineral density and visceral fat. Bone 33: 646-651.
74. Lentzsch S, Gries M, Janz M, Bargou R, Dorken B, Mapara MY, (2003). Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 101: 3568-3573.
75. Levy J, Roodman GD, (2009). The role of bisphosphonates in multiple myeloma. Curr Hematol Malig Rep 4: 108-112.
76. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, et-al. (2009). Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24: 578-588.
77. Li X, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Grisanti M, et-al. (2010). Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res 25: 2647-2656.
78. Lipton ASG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, et-al. (2007). Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 25: 4431-4437.
79. Lipton ASG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, et-al. (2008). Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res 14: 6690-6696.
80. Liu Y, Dong Y, Jiang QL, Zhang B, Hu AM, (2013). Bruton's tyrosine kinase: potential target in human multiple myeloma. Leuk Lymphoma 55: 177-181.
81. Ludwig H, Miguel JS, Dimopoulos MA, Palumbo A, Garcia Sanz R, Powles R, et-al. (2013). International Myeloma Working Group recommendations for global myeloma care. Leukemia 28: 981-992.
82. Mao B, Wu W, Li Y, Hoppe D, Stannek P, Glinka A, et-al. (2001). LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 411: 321-325.
83. Martin TJ, Allan EH, Ho PW, Gooi JH, Quinn JM, Gillespie MT, et-al. (2010). Communication between ephrinB2 and EphB4 within the osteoblast lineage. Adv Exp Med Biol 658: 51-60.
84. Masi L, Malentacchi C, Campanacci D, Franchi A, (2002). Transforming growth factor-beta isoform and receptor expression in chondrosarcoma of bone. Virchows Arch 440: 491-497.
85. McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, et-al. (2014). Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370: 412-420.
86. McColm J, Hu L, Womack T, Tang CC, Chiang AY, (2013). Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. J Bone Miner Res 29: 935-943.
87. Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M, et-al. (2007). Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 67: 1783-1792.
88. Melton LJ 3rd, Kyle RA, Achenbach SJ, Oberg AL, Rajkumar SV, (2005). Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res 20: 487-493.
89. Menu E, De Leenheer E, De Raeve H, Coulton L, Imanishi T, Miyashita K, et-al. (2006). Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model. Clin Exp Metastasis 23: 291-300.
90. Morgan GJ, Child JA, Gregory WM, Szubert AJ, Cocks K, Bell SE, et-al. (2011). Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncol 12: 743-752.
91. Morgan GJ, Davies FE, Gregory WM, Szubert AJ, Bell SE, Drayson MT, et-al. (2012). Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial. Blood 119: 5374-5383.
92. Mundy GR, Elefteriou F, (2006). Boning up on ephrin signaling. Cell 126: 441-443.
93. Munemasa S, Sakai A, Kuroda Y, Okikawa Y, Katayama Y, Asaoku H, et-al. (2008). Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation. Int J Oncol 33: 129-136.
94. Munshi NC, Beck JT, Bensinger W, Facon T, Stockerl-Goldstein K, Baz R, et-al. (2012). Early evidence of anabolic bone activity of BHQ880, a fully human anti-dkk1 neutralizing antibody: results of a Phase 2 study in previously untreated patients with smoldering multiple myeloma at risk for progression. Blood 120: Abstract 331.
95. Narayanan P, (2013). Denosumab: a comprehensive review. South Asian J Cancer 2: 272-277.
96. Neri P, Kumar S, Fulciniti MT, Vallet S, Chhetri S, Mukherjee S, et-al. (2007). Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res 13: 5903-5909.
97. Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W, et-al. (2004). Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 103: 689-694.
98. Oba Y, Lee JW, Ehrlich LA, Chung HY, Jelinek DF, Callander NS, et-al. (2005). MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Exp Hematol 33: 272-278.
99. Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M, et-al. (2011). Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res 26: 1012-1021.
100. Oshima K, Nampei A, Matsuda M, Iwaki M, Fukuhara A, Hashimoto J, et-al. (2005). Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun 331: 520-526.
101. Ottewell PD, Monkkonen H, Jones M, Lefley DV, Coleman RE, Holen I, (2008). Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 100: 1167-1178.
102. Oyajobi BO, Garrett IR, Gupta A, Flores A, Esparza J, Munoz S, et-al. (2007). Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. Br J Haematol 139: 434-438.
103. Oyayobi B, Williams PJ, Pulkrabek D, Franchin G, Sherry B, Mundy GR, (2001). In vivo osteoclastogenic effects of the CC chemokine, macrophage inflammatory protein (MIP)-1α. Bone 27: S81.
104. Padhi D, Jang G, Stouch B, Fang L, Posvar E, (2011). Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26: 19-26.
105. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T, (1994). The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 78: 773-785.
106. Palombella VJ, Conner EM, Fuseler JW, Destree A, Davis JM, Laroux FS, et-al. (1998). Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci U S A 95: 15671-15676.
107. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, et-al. (2001). Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A 98: 11581-11586.
108. Pennisi A, Li X, Ling W, Khan S, Zangari M, Yaccoby S, (2009a). The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol 84: 6-14.
109. Pennisi A, Ling W, Li X, Khan S, Shaughnessy JD Jr, Barlogie B, et-al. (2009b). The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth. Blood 114: 1803-1812.
110. Pozzi S, Fulciniti M, Yan H, Vallet S, Eda H, Patel K, et-al. (2013). In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma. Bone 53: 487-496.
111. Qian J, Zheng Y, Zheng C, Wang L, Qin H, Hong S, et-al. (2012). Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma. Blood 119: 161-169.
112. Qiang YW, Walsh K, Yao L, Kedei N, Blumberg PM, Rubin JS, et-al. (2005). Wnts induce migration and invasion of myeloma plasma cells. Blood 106: 1786-1793.
113. Raje N, Faber EA, Richardson PG, Schiller GJ, Hohl RJ, Cohen AD, et-al. (2012). Phase 1 study of Tabalumabm a human anti-BAFF antibody and bortezomi in patients with previously-treated multiple myeloma. Blood 120: Abstract 447.
114. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC, (2005). Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23: 630-639.
115. Richards JB, Valdes AM, Burling K, Perks UC, Spector TD, (2007). Serum adiponectin and bone mineral density in women. J Clin Endocrinol Metab 92: 1517-1523.
116. Risbridger GP, Mellor SL, McPherson SJ, Schmitt JF, (2001). The contribution of inhibins and activins to malignant prostate disease. Mol Cell Endocrinol 180: 149-153.
117. Rogers MJ, Crockett JC, Coxon FP, Monkkonen J, (2011). Biochemical and molecular mechanisms of action of bisphosphonates. Bone 49: 34-41.
118. Roodman GD, Dougall WC, (2008). RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev 34: 92-101.
119. Ruckle J, Jacobs M, Kramer W, Pearsall AE, Kumar R, Underwood KW, et-al. (2009). Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res 24: 744-752.
120. Rushworth SA, Bowles KM, Barrera LN, Murray MY, Zaitseva L, MacEwan DJ, (2013). BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-kappaB. Cell Signal 25: 106-112.
121. Seidel C, Hjertner O, Abildgaard N, Heickendorff L, Hjorth M, Westin J, et-al. (2001). Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 98: 2269-2271.
122. Shinoda Y, Yamaguchi M, Ogata N, Akune T, Kubota N, Yamauchi T, et-al. (2006). Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. J Cell Biochem 99: 196-208.
123. Shinohara M, Koga T, Okamoto K, Sakaguchi S, Arai K, Yasuda H, et-al. (2008). Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. Cell 132: 794-806.
124. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et-al. (1997). Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309-319.
125. Sternberg D, Honigwachs-sha'anani J, Brosh N, Malik Z, Burstein Y, Zipori D, (1995). Restrictin-P/stromal activin A, kills its target cells via an apoptotic mechanism. Growth Factors 12: 277-287.
126. Stopeck ATLA, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, et-al. (2010). Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28: 5132-5139.
127. Sugatani T, Alvarez UM, Hruska KA, (2003). Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors. J Cell Biochem 90: 59-67.
128. Sutherland MK, Geoghegan JC, Yu C, Turcott E, Skonier JE, Winkler DG, et-al. (2004). Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone 35: 828-835.
129. Swarbrick MM, Havel PJ, (2008). Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab Syndr Relat Disord 6: 87-102.
130. Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L, et-al. (2006). Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 66: 6675-6682.
131. Tai YT, Chang BY, Kong SY, Fulciniti M, Yang G, Calle Y, et-al. (2012). Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood 120: 1877-1887.
132. Takyar FM, Tonna S, Ho PW, Crimeen-Irwin B, Baker EK, Martin TJ, et-al. (2013). EphrinB2/EphB4 inhibition in the osteoblast lineage modifies the anabolic response to parathyroid hormone. J Bone Miner Res 28: 912-925.
133. Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J, et-al. (2003). Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102: 1064-1069.
134. Terpos E, Christoulas D, Katodritou E, Bratengeier C, Gkotzamanidou M, Michalis E, et-al. (2012a). Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy. Int J Cancer 131: 1466-1471.
135. Terpos E, Kastritis E, Christoulas D, Gkotzamanidou M, Eleutherakis-Papaiakovou E, Kanellias N, et-al. (2012b). Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy. Ann Oncol 23: 2681-2686.
136. Terpos ECD, Katodritou E, Kastritis E, Papatheodoru A, Kyrtsonis MC, Papanikolaou X, et-al. (2011). The combination of lenalidomide and dexamethasone (RD) reduces bone resorption in responding patients with relapsed/refractory multiple myeloma (MM) but has no effect on bone formation: results of a retrospective analysis and a prospective study on 205 patients, on behalf of the Greek myeloma study group. Haematologica 96 (Suppl. 1): abstract P-126.
137. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, et-al. (2003). The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349: 2483-2494.
138. Vallet S, Mukherjee S, Vaghela N, Hideshima T, Fulciniti M, Pozzi S, et-al. (2010). Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci U S A 107: 5124-5129.
139. Vallet S, Pozzi S, Patel K, Vaghela N, Fulciniti MT, Veiby P, et-al. (2011). A novel role for CCL3 (MIP-1alpha) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function. Leukemia 25: 1174-1181.
140. Varshavsky A, (1997). The ubiquitin system. Trends Biochem Sci 22: 383-387.
141. Vega D, Maalouf NM, Sakhaee K, (2007). CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab 92: 4514-4521.
142. de Weers M, Mensink RG, Kraakman ME, Schuurman RK, Hendriks RW, (1994). Mutation analysis of the Bruton's tyrosine kinase gene in X-linked agammaglobulinemia: identification of a mutation which affects the same codon as is altered in immunodeficient xid mice. Hum Mol Genet 3: 161-166.
143. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, et-al. (2003). Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22: 6267-6276.
144. Yamaguchi N, Kukita T, Li YJ, Martinez Argueta JG, Saito T, Hanazawa S, et-al. (2007). Adiponectin inhibits osteoclast formation stimulated by lipopolysaccharide from Actinobacillus actinomycetemcomitans. FEMS Immunol Med Microbiol 49: 28-34.
145. Zangari M, Terpos E, Zhan F, Tricot G, (2012). Impact of bortezomib on bone health in myeloma: a review of current evidence. Cancer Treat Rev 38: 968-980.
146. Zavrski I, Krebbel H, Wildemann B, Heider U, Kaiser M, Possinger K, et-al. (2005). Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function. Biochem Biophys Res Commun 333: 200-205.
147. Zhao C, Irie N, Takada Y, Shimoda K, Miyamoto T, Nishiwaki T, et-al. (2006). Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 4: 111-121.
148. Zweidler-Mckay PA, Grimes HL, Flubacher MM, Tsichlis PN, (1996). Gfi-1 encodes a nuclear zinc finger protein that binds DNA and functions as a transcriptional repressor. Mol Cell Biol 16: 4024-4034.